Cytoreduction, DLI, or mobilized peripheral blood progenitors

Annals of Hematology

Volumn 81, Issue SUPPL. 2, 2002, Pages

  Kolb, H J ^a   Schmid, Ch ^a   Weisser, M ^a   Pihusch, M ^a   Tischer, J ^a   Pihusch, R ^a   Stoetzer, O ^a   Ledderose, G ^a   Schleuning, M ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALLOTRANSPLANTATION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE DEPLETION; LYMPHOCYTE TRANSFUSION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHUMAN; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RECURRENCE RISK; STEM CELL MOBILIZATION; T LYMPHOCYTE; TREATMENT INDICATION; WHOLE BODY RADIATION;

BLOOD COMPONENT REMOVAL; BLOOD DONORS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; LYMPHOCYTE TRANSFUSION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING;

EID: 0036992981     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE et al. (1975) Bone marrow transplantation. N Engl J Med 292:832-843.
2. Rodt H, Kolb HJ, Netzel B, Rieder I, Janka G, Belohradsky B et al. (1979) GVHD suppression by incubation of bone marrow grafts with anti-T- cell globulin: effect in the canine model and application to clinical bone marrow transplantation. Transplant Proc 11:962-966.
3. Kolb HJ, Rodt H, Netzel B, Hale G, Haas RJ, Bender Goetze C et al. (1985) In vitro treatment of marrow with ATCG or Campath 1 for prophylaxis of GVHD - Results of the AG-KMT München. Exp Hematol 13 Suppl 17:147.
4. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555-562.
5. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041-2050.
6. Storb R, Epstein RB, Rudolph RH, and Thomas ED (1970) The effect of prior transfusion on marrow grafts between histocompatible canine siblings. J Immunol 105(3):627-633.
7. Quesenberry PJ, Zhong S, Wang H, and Stewart M (2001) Allogeneic chimerism with low-dose irradiation, antigen presensitization, and costimulator blockade in H-2 mismatched mice. Blood 97(2):557-564.
8. Kolb HJ, Thierfelder S, Baumann P, and Balk O (1971) Conditioning recipients of hemopoietic cells with antilymphocyte serum (ALS) and partial body irradiation. Rev Europ Etudes Clin et Biol 16:810-814.
9. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97(11):3390-3400.
10. Losslein LK, Kolb HJ, Porzsolt S, Schaffer E, Scholz S, Meissner H et al. (1987) Hyperfractionation of total-body irradiation and engraftment of marrow from DLA-haploidentical littermates. Transplant Proc 19:2707-2708.
11. Reisner Y, and Martelli MF (2000) Transplantation tolerance induced by "mega dose" CD34+ cell transplants. Exp Hematol 28(2):119-127.
12. Martin PJ, Akatsuka Y, Hahne M, and Sale G (1998) Involvement of donor T-cell cytotoxic effector mechanisms in preventing allogeneic marrow graft rejection. Blood 92(6): 2177-2181.
13. Aversa F, Tabilio A, Terenzi A, Velardi A, Falzetti F, Giannoni C et al. (1994) Successful engraftment of T-cell depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 84:3948-3955.
14. Pan L, Delmonte J, Jalonen CK, and Ferrara JLM (1995) Pre-treatment of donor mice with granulocyte colony-stimulating factor polarizes donor T-lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 86:4422.
15. Körbling M, Przepiorka D, Huh YO, Engel H, Van Besien K, Giralt S et al. (1995) Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts. Blood 85:1659-1665.
16. Elmaagacli AH, Beelen DW, Opalka B, Seeber S, and Schaefer UW (1999) The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow. Blood 94(2):384-389.
17. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A et al. (1996) Randomised trial of filgastrim-mobilised peripheral blood progenitor cell transplantation in lymphoma patients. Lancet 347:353-357.
18. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R et al. (2001) Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344(3):175-181.
19. Handgretinger R, Klingebiel T, Lang P, Schumm M, Neu S, Geiselhart A et al. (2001) Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant 27(8):777-783.
20. Reich-Zeliger S, Zhao Y, Krauthgamer R, Bachar-Lustig E, and Reisner Y (2000) Anti-third party CD8+ CTLs as potent veto cells: coexpression of CD8 and FasL is a prerequisite. Immunity 13(4):507-515.
21. Kolb H-J, Hoetzl F, Guenther W, Fuehrer M, Schmid C, Ledderose G et al. (2000) CD-6 negative blood stem cells facilitating HLA-haploidentical transplantation in the treatment of advanced leukemia. Blood 96[11], 208a. Ref Type: Abstract
22. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097-2100.
23. Kolb HJ, Socie G, Duell T, van Lint MT, Tichelli A, Apperley JF et al. (1999) Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med 131(10):738-744.
24. Johnson BD, Drobyski WR, and Truitt RL (1993) Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplant 11:329-336.
25. Kolb HJ, Günther W, Schumm M, Holler E, Wilmanns W, and Thierfelder S (1997) Adoptive immunotherapy in canine chimeras. Transplantation 63:430-436.
26. Johnson BD, Becker EE, LaBelle JL, and Truitt RL (1999) Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy. J Immunol 163(12):6479-6487.
27. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J et al. (1999) Prevention of graft-versus-host disease by inactivaion ofhost antigen-presenting cells. Science 285: 412-415.
28. Theobald M, Nierle T, Bunjes D, Arnold R, and Heimpel H (1992) Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. N Engl J Med 327:1613-1617.
29. Weiden PL, Storb R, Tsoi M-S, Graham TC, Lerner KG, and Thomas ED (1976) Infusion of donor lymphocytes into stable canine radiation chimeras: Implications for mechanism of transplantation tolerance. J Immunol 116:1212-1219.
30. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F et al. (1995) Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86:1261-1268.
31. Dazzi F, Craddock C, Szydlo R, Kaeda J, Montefusco E, Kanfer EJ et al. (1999) Adoptive immunotherapy with donr lymphocytes for relapse of chronic myeloid leukemia (CML) after allogeneic stem cell transplant (SCT): Factors influencing the effective cell dose (ECD). Blood 92 [10 Suppl1], 494a.
32. Chen X, Regn S, Raffegerst S, Kolb HJ, and Roskrow M (2000) Interferon alpha in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemia. Br J Haematol 111(2):596-607.
33. Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LLM, and Verdonck L (1997) Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 90:4206-4211.
34. Choudhury BA, Liang J, Thomas EK, Flores-Romo L, Xie QS, Agusala K et al. (1999) Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous anti-leukemic T-cell responses. Blood 93(3):780-786.
35. Woiciechowsky A, Regn S, Kolb H-J, and Roskrow M (2001) Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukaemia-specific cytotoxic T cell response from patients with acute myeloid leukaemia. Leukemia 15, 246-255.
36. Schmid C, Lange C, Salat C, Stoetzer O, Ledderose G, Muth A et al. (1999) Treatment of recurrent acute leukemia after marrow transplantation with donor cells and GM-CSF. Blood 94[10 Suppl 1], 668a.
37. Schmid C, Alessandrino EP, Bunjes D, Ferrant A, Frassoni F, Gluckman E et al. (2000) Treatment of relapsed AML and MDS after allogeneic stem cell tgransplantation with donor lymphocyte transfusion - A retrospective analysis of EBMT results. Blood 96 [11], 477a.
38. Bonini C, Ferrari G, Verzelletti S, Servida P, Zappone E, Ruggieri L et al. (1997) HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276:1719-1724.
39. Weissinger EM, Franz M, Voss C, Kremmer E, and Kolb H-J. (2000) Expression of HSV-TK suicide gene in primary T-lymphocytes: The dog as a preclinical model. Cytokines, Cellular & Molecular Therapy 6(1):25-33.
40. Li Z, Dullmann J, Schiedlmeier B, Schmidt M, von Kalle C, Meyer J et al. (2002) Murine leukemia induced by retroviral gene marking. Science 296(5567):497.